Market failure and the poverty of new drugs in maternal health
2008

Market Failure and the Lack of New Drugs for Maternal Health

publication Evidence: high

Author Information

Author(s): Nicholas M. Fisk, Rifat Atun

Primary Institution: Imperial College London

Hypothesis

Have the market models for pharmaceuticals in developed countries and international mechanisms failed to address the needs of maternal health?

Conclusion

The study concludes that there is a significant under-investment in maternal health drugs, with only one new class licensed in the last 20 years.

Supporting Evidence

  • Only 17 drugs are under active development for maternal health, which is less than 3% of the pipeline in cardiovascular health.
  • Only one new class of drug has been licensed for obstetric conditions in the last 20 years.
  • 99% of maternal deaths occur in developing countries, often due to preventable conditions.

Takeaway

There aren't enough new medicines being developed for pregnant women, which is a big problem because many women and babies need better treatments.

Methodology

The study involved a search of the Pharmaprojects database to track drugs under development for maternal health and compared this with other therapeutic areas.

Potential Biases

The reliance on off-label drug use and the lack of clinical trials for pregnant women may introduce bias in treatment safety and efficacy.

Limitations

The study may have missed some agents due to the limitations of the database and search methods used.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0050022

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication